Monday 21 March | |
Photo-Me International PLC | Full Year Results |
Spectral MD Holdings Ltd | Full Year Results |
Sthree PLC | Trading Statement |
Tuesday 22 March | |
Alliance Pharma PLC | Full Year Results |
BioPharma Credit PLC | Full Year Results |
Circassia Group PLC | Full Year Results |
Diaceutics PLC | Full Year Results |
Diurnal Group PLC | Full Year Results |
IQGeo Group PLC | Full Year Results |
Longboat Energy PLC | Full Year Results |
Luceco PLC | Full Year Results |
MaxCyte Inc | Full Year Results |
MP Evans Group PLC | Full Year Results |
Oxford Nanopore Technologies PLC | Full Year Results |
Pebble Group PLC | Full Year Results |
Real Estate Investors PLC | Full Year Results |
Sabre Insurance Group PLC | Full Year Results |
ScS Group PLC | Half Year Results |
Softcat PLC | Half Year Results |
Staffline Group PLC | Full Year Results |
Trustpilot Group PLC | Full Year Results |
YouGov PLC | Half Year Results |
Zotefoams PLC | Full Year Results |
Wednesday 23 March | |
Dignity PLC | Full Year Results |
ECSC Group PLC | Full Year Results |
Henry Boot PLC | Full Year Results |
Judges Scientific PLC | Full Year Results |
Pendragon PLC | Full Year Results |
Saga PLC | Full Year Results |
SigmaRoc PLC | Full Year Results |
Thursday 24 March | |
Arbuthnot Banking Group PLC | Full Year Results |
Atalaya Mining PLC | Full Year Results |
Big Technologies PLC | Full Year Results |
Biome Technologies PLC | Full Year Results |
Bonhill Group PLC | Full Year Results |
Bridepoint Group PLC | Full Year Results |
CVS Group PLC | Half Year Results |
Energean PLC | Full Year Results |
EnQuest PLC | Full Year Results |
Eve Sleep PLC | Full Year Results |
International Public Partnerships Ltd | Full Year Results |
Kin & Carta PLC | Full Year Results |
Next PLC | Full Year Results |
Safestyle UK PLC | Full Year Results |
Secure Trust Bank PLC | Full Year Results |
Sopheon PLC | Full Year Results |
Starwood European Real Estate Ltd | Full Year Results |
WAG Payment Solutions PLC | Full Year Results |
Friday 25 March | |
Electrocomponents PLC | Trading Statement |
Faron Pharmaceuticals Ltd | Full Year Results |
Smiths Group | Half Year Results |
United Utilities Group PLC | Trading Statement |
Wickes Group PLC | Full Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.
Read more